Leerink Partners analyst Jonathan Chang reiterated a Buy rating on NovoCure on July 24 and set a price target of $33.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jonathan Chang has given his Buy rating due to a combination of factors surrounding NovoCure’s recent performance and future prospects. The company reported strong financial results for the second quarter of 2025, surpassing revenue expectations with a total of $158.8 million, which was higher than the consensus estimate. This growth was primarily driven by an increase in active patient numbers across major markets, indicating a solid demand for their products.
Moreover, while the initial metrics for the launch of Optune Lua in non-small cell lung cancer (NSCLC) were mixed, there was a notable increase in prescriptions and active patients, suggesting potential for future growth. Additionally, NovoCure’s pipeline progress remains on track, with significant developments such as the anticipated submission of a Premarket Approval application for pancreatic cancer treatment. These factors, combined with the existing value of Optune in glioblastoma and the potential for success in upcoming regulatory decisions, contribute to a positive outlook for NovoCure’s stock.
In another report released on July 25, H.C. Wainwright also reiterated a Buy rating on the stock with a $38.00 price target.
NVCR’s price has also changed dramatically for the past six months – from $26.330 to $12.540, which is a -52.37% drop .